Docket No.: 255352001800

(PATENT)

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mark William James FERGUSON et al.

Application No.: 10/522,222

Filed: (Int'l) July 23, 2003

For: USE OF FURIN INHIBITORS IN THE

TREATMENT OF FIBROSIS AND SCARRING (AS AMENDED)

Confirmation No.: 1601

Art Unit: 1654

Examiner: Satyanarayan R. Gudibande, Ph.D.

## COMMUNICATION TO ACCOMPANY A REQUEST FOR CONTINUED EXAMINATION

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants have filed a Request for Continued Examination in order to ensure entry of the amendment submitted with the Response to final rejection, which Response was submitted electronically on 5 August 2008. In an Advisory Action subsequent to this Response, the Office states that the specification does not support claims for the application of the furin inhibitor "directly" to the site of the wound. However, applicants believe this is in error for the following reasons:

sd-442459 1

Application No.: 10/522,222 Docket No.: 255352001800

First, claim 1 of the PCT publication which forms the specification for the present case requires that a convertase inhibitor (narrowed in claim 2 to a furin inhibitor) is "topically applied to the site of a wound." Applicants believe this is the same as applying the inhibitor directly to the site of the wound. In addition, the second full paragraph on page 12 states that the medicament is applied to the site where a wound may be formed, again implying direct application. In addition, the bridging paragraph between page 11 and 12 states that disadvantages applicable to topical application of convertase inhibitors are not applicable in the invention method because in this case, "the effect of the inhibitors is directed to the region of the wound." The previous paragraph on page 11 further clarifies that the application is so as to produce "localized" inhibition of convertase activity.

In view of these locations for support, applicants believe that the claim language is indeed supported by the specification as filed. Accordingly, the proposed amendment does not constitute new matter.

sd-442459 2

Application No.: 10/522,222 Docket No.: 255352001800

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit**Account No. 03-1952 referencing docket No. 255352001800.

Respectfully submitted,

Dated: September 17, 2008 By: / Kate H. Murashige /

Kate H. Murashige Registration No.: 29,959 MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100 San Diego, California 92130-2040

Telephone: (858) 720-5112 Facsimile: (858) 720-5125

sd-442459 3